CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trial An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management Select Drug-Drug Interactions With Direct Oral Anticoagulants Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation The mSToPS Randomized Clinical Trial Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock Generalizing Intensive Blood Pressure Treatment to Adults With Diabetes Mellitus

Consensus06 April 2020

JOURNAL: JACC Cardiovasc Interv and Catheter Cardiovasc In Article Link

Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement

PB Shah, FGP Welt, E Mahmud et al. Keywords: COVID-19; TAVR; valvular and structural heart disease; HF; triage intervention

Full Text PDF

The COVID-19 pandemic has strained health care resources around the world causing many institutions to curtail or stop elective procedures. This has resulted in the inability to care for patients valvular and structural heart disease (SHD) in a timely fashion potentially placing these patients at increased risk for adverse cardiovascular complications including congestive heart failure and death. The effective triage of these patients has become challenging in the current environment as clinicians have had to weigh the risk of bringing susceptible patients into the hospital environment during the COVID-19 pandemic versus the risk of delaying a needed procedure. In this document, we suggest guidelines as to how to triage patients in need of SHD interventions and provide a framework of how to decide when it may be appropriate to proceed with intervention despite the ongoing pandemic. In particular, we address the triage of patients in need of trans-catheter aortic valve replacement and percutaneous mitral valve repair. We also address procedural issues and considerations for the function of structural heart disease teams during the COVID-19 pandemic.